Pimasertib hydrochloride is under clinical development by Day One Biopharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pimasertib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pimasertib hydrochloride overview

Pimasertib hydrochloride is under development for the treatment of  solid tumors. It was under development for metastatic malignant cutaneous melanoma, acute myeloid leukemia, hepatocellular carcinoma, solid tumors, metastatic colorectal cancer, metastatic pancreatic cancer and other hematological malignancies. The drug candidate is administered by oral route. It acts as an inhibitor of mitogen-activated protein Kinase-1/2 (MEK 1/2). Pimasertib in combination with pilaralisib was under development for the treatment of advanced or metastatic solid tumors.

Day One Biopharmaceuticals overview

Day One Biopharmaceuticals is a biopharmaceutical company. It discovers and develops drugs for addressing the unmet medical needs of cancers associated with genetic mutations in rapidly accelerated fibrosarcoma (RAF) family kinases. The company investigates its lead product candidate: DAY101 (TAK-580), a pan-RAF inhibitor for the treatment of low-grade glioma and cancers that foster genetic alterations in RAF. It works in partnership with research and the parent advocacy communities to advance the development of medicines for the treatment of various cancer types. Day One Biopharmaceuticals is headquartered in Brisbane, California, the US.

For a complete picture of Pimasertib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.